If we focus solely on the pharmaceutical sector, i.e. the production and consumption of medicines, this sector emits 26.3 million tonnes of CO2 per year, according to a study carried out by Leem in 2022. In its latest report, the Shift Project estimates healthcare sector emissions at 49 million tonnes of CO2 per year, representing almost 8% of the country's carbon footprint. Among the main sources of emissions are the purchase of medicines (33%), medical devices such as gloves, syringes and compresses (22%), and the transportation of patients and caregivers (16%).
With a view to reducing its carbon footprint, the pharmaceutical sector has drawn up a decarbonization plan. It sets targets in line with those of the Paris Agreement, which aims to limit global warming to between 1.5°C and 2°C.
By 2030, the sector is aiming to reduce its CO2 emissions directly linked to product manufacture and energy consumption by no less than 50%.
Indirect emissions are expected to fall by 25%. These are emissions not directly linked to the manufacture of a drug, such as procurement, transport or use.
Leem would like to systematize the carbon footprint of all companies, 60% of which do not do so at present, and to put in place so-called "complex" actions in terms of resources by companies. To take action, pharmaceutical companies would like to receive a financial boost from the public authorities.